Multi -provinces in China have followed up medical anti -corruption.

(Beijing Comprehensive News) Anti -corruption actions in the field of pharmaceuticals in China have continued to expand. As of Tuesday (August 8), eight provinces have followed up centralized rectification, and senior personnel of listed pharmaceutical companies have been reported to investigate.

According to surging news reports, the health regulatory departments of Jiangsu, Shanghai, Beijing, and Hainan provinces have adopted anti -corruption operations for the medical field. The disciplinary commissions of the Tibet Autonomous Region, Shaanxi, Shanxi, and Shandong provinces have also spoke to the medical field.

The official website of the China National Health and Health Commission released news earlier. The State Health and Health Commission and the State Administration of Market Supervision and the State Drug Administration and other relevant departments jointly held video conferences to deploy a one -year national pharmaceutical field.Work.Subsequently, many provinces in China issued relevant notices.

According to the Securities Daily, there have been recent listed pharmaceutical companies that have been left -level or investigated by high -level personnel.In addition, many academic conferences in the pharmaceutical industry have announced the extension or cancellation, and many pharmaceutical companies and medical institutions have also launched self -examination and self -correction work to make compliant rectifications on the agenda.

A marketing department of a medical institution revealed that some listed pharmaceutical companies have selected medical forums in the resort, "named academic, but tourism."

Lawyer Fu Jian, director of Henan Zejou Law Firm, said that there are some companies in the pharmaceutical industry to implement the chaos of "gold sales" under the guise of academic conferences.In terms of expenses.

Lin Cun, chairman of Senrui Investment, has publicly stated that the main goal of anti -corruption in medicine is to combat irregular and illegal interest chains in the medical system and guide the healthy and healthy development of the industry.The efficacy does not have competitiveness, and drugs and medical devices that occupy the market through the market, such as "selling gold", will be accelerated. It is actually good for companies that really have innovative value and meet clinical needs.